Christine A Rabinak1,2,3,4,5, Ashley Blanchette6, Nicole L Zabik6,7, Craig Peters6, Hilary A Marusak8,9, Allesandra Iadipaolo6, Farrah Elrahal6. 1. Department of Pharmacy Practice, Wayne State University, 259 Mack Ave, Suite 2190, Detroit, MI, 48201, USA. rabinak@wayne.edu. 2. Translational Neuroscience Program, Wayne State University, Detroit, MI, USA. rabinak@wayne.edu. 3. Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA. rabinak@wayne.edu. 4. Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA. rabinak@wayne.edu. 5. Merrill Palmer Skillman Institute for Child and Family Development, Wayne State University, Detroit, MI, USA. rabinak@wayne.edu. 6. Department of Pharmacy Practice, Wayne State University, 259 Mack Ave, Suite 2190, Detroit, MI, 48201, USA. 7. Translational Neuroscience Program, Wayne State University, Detroit, MI, USA. 8. Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA. 9. Merrill Palmer Skillman Institute for Child and Family Development, Wayne State University, Detroit, MI, USA.
Abstract
RATIONALE: Excessive fear and anxiety, coupled with corticolimbic dysfunction, are core features of stress- and trauma-related psychopathology, such as posttraumatic stress disorder (PTSD). Interestingly, low doses of ∆9-tetrahydrocannabinol (THC) can produce anxiolytic effects, reduce threat-related amygdala activation, and enhance functional coupling between the amygdala and medial prefrontal cortex and adjacent rostral cingulate cortex (mPFC/rACC) during threat processing in healthy adults. Together, these findings suggest the cannabinoid system as a potential pharmacological target in the treatment of excess fear and anxiety. However, the effects of THC on corticolimbic functioning in response to threat have not be investigated in adults with trauma-related psychopathology. OBJECTIVE: To address this gap, the present study tests the effects of an acute low dose of THC on corticolimbic responses to threat in three groups of adults: (1) non-trauma-exposed healthy controls (HC; n = 25), (2) trauma-exposed adults without PTSD (TEC; n = 27), and (3) trauma-exposed adults with PTSD (n = 19). METHODS: Using a randomized, double-blind, placebo-controlled, between-subjects design, 71 participants were randomly assigned to receive either THC or placebo (PBO) and subsequently completed a well-established threat processing paradigm during functional magnetic resonance imaging. RESULTS: In adults with PTSD, THC lowered threat-related amygdala reactivity, increased mPFC activation during threat, and increased mPFC-amygdala functional coupling. CONCLUSIONS: These preliminary data suggest that THC modulates threat-related processing in trauma-exposed individuals with PTSD, which may prove advantageous as a pharmacological approach to treating stress- and trauma-related psychopathology.
RCT Entities:
RATIONALE: Excessive fear and anxiety, coupled with corticolimbic dysfunction, are core features of stress- and trauma-related psychopathology, such as posttraumatic stress disorder (PTSD). Interestingly, low doses of ∆9-tetrahydrocannabinol (THC) can produce anxiolytic effects, reduce threat-related amygdala activation, and enhance functional coupling between the amygdala and medial prefrontal cortex and adjacent rostral cingulate cortex (mPFC/rACC) during threat processing in healthy adults. Together, these findings suggest the cannabinoid system as a potential pharmacological target in the treatment of excess fear and anxiety. However, the effects of THC on corticolimbic functioning in response to threat have not be investigated in adults with trauma-related psychopathology. OBJECTIVE: To address this gap, the present study tests the effects of an acute low dose of THC on corticolimbic responses to threat in three groups of adults: (1) non-trauma-exposed healthy controls (HC; n = 25), (2) trauma-exposed adults without PTSD (TEC; n = 27), and (3) trauma-exposed adults with PTSD (n = 19). METHODS: Using a randomized, double-blind, placebo-controlled, between-subjects design, 71 participants were randomly assigned to receive either THC or placebo (PBO) and subsequently completed a well-established threat processing paradigm during functional magnetic resonance imaging. RESULTS: In adults with PTSD, THC lowered threat-related amygdala reactivity, increased mPFC activation during threat, and increased mPFC-amygdala functional coupling. CONCLUSIONS: These preliminary data suggest that THC modulates threat-related processing in trauma-exposed individuals with PTSD, which may prove advantageous as a pharmacological approach to treating stress- and trauma-related psychopathology.
Authors: S Bhattacharyya; Z Atakan; R Martin-Santos; J A Crippa; J Kambeitz; D Prata; S Williams; M Brammer; D A Collier; P K McGuire Journal: Mol Psychiatry Date: 2012-01-31 Impact factor: 15.992
Authors: Sarah J Bujarski; Matthew T Feldner; Sarah F Lewis; Kimberly A Babson; Casey D Trainor; Ellen Leen-Feldner; Christal L Badour; Marcel O Bonn-Miller Journal: Addict Behav Date: 2011-09-08 Impact factor: 3.913
Authors: Jason T Buhle; Jennifer A Silvers; Tor D Wager; Richard Lopez; Chukwudi Onyemekwu; Hedy Kober; Jochen Weber; Kevin N Ochsner Journal: Cereb Cortex Date: 2013-06-13 Impact factor: 5.357
Authors: Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire Journal: Neuropsychopharmacology Date: 2009-11-18 Impact factor: 7.853
Authors: Richard A Bryant; Andrew H Kemp; Kim L Felmingham; Belinda Liddell; Gloria Olivieri; Anthony Peduto; Evian Gordon; Leanne M Williams Journal: Hum Brain Mapp Date: 2008-05 Impact factor: 5.038
Authors: Julia D Buckner; Paige E Morris; Cristina N Abarno; Nina I Glover; Elizabeth M Lewis Journal: Curr Psychiatry Rep Date: 2021-04-17 Impact factor: 5.285
Authors: David M Lovinger; Yolanda Mateo; Kari A Johnson; Sheila A Engi; Mario Antonazzo; Joseph F Cheer Journal: Nat Rev Neurosci Date: 2022-02-28 Impact factor: 34.870
Authors: Shreya Desai; Breanna Borg; Carrie Cuttler; Kevin M Crombie; Christine A Rabinak; Matthew N Hill; Hilary A Marusak Journal: Cannabis Cannabinoid Res Date: 2021-12-03
Authors: Kevin M Crombie; Anneliis Sartin-Tarm; Kyrie Sellnow; Rachel Ahrenholtz; Sierra Lee; Megan Matalamaki; Neda E Almassi; Cecilia J Hillard; Kelli F Koltyn; Tom G Adams; Josh M Cisler Journal: Psychoneuroendocrinology Date: 2021-07-09 Impact factor: 4.693
Authors: Ana Maria Raymundi; Thiago R da Silva; Jeferson M B Sohn; Leandro J Bertoglio; Cristina A Stern Journal: BMC Psychiatry Date: 2020-08-26 Impact factor: 3.630